ICH M Guidelines: how to pass FDA/EMA audits with perfect CTD dossiers

How to pass FDA/EMA audits using the ICH M Guidelines: audit-ready CTD dossiers

Introduction

Regulatory inspections no longer focus solely on manufacturing facilities: EMA, FDA and PMDA auditors increasingly scrutinise the quality of CTD/eCTD dossiers.
As a result, the ICH M Guidelines have become an essential tool to ensure consistency, completeness and traceability.

A poorly written CTD generates more deviations than a non-compliant manufacturing process.
Many inspection findings relate to CMC errors, inconsistencies between modules, insufficient stability data or incomplete CSR — all areas covered by ICH M.

In-depth regulatory analysis

ICH M4Q – Quality / Module 3

Key concerns according to authorities:

  • justification of impurities
  • no discussion of stability trends
  • incomplete analytical method validation
  • process description not aligned with clinical batches
  • specifications not supported by data

ICH M4E – Efficacy and Safety

Expectations include:

  • complete CSR
  • consistent and accurate synopses
  • integrated safety evaluation
  • PK/PD analysis compliant with guidelines

ICH M8 – eCTD

Authorities verify:

  • lifecycle consistency
  • correct use of replace operations
  • duplicate leaf documents
  • envelope metadata errors
  • broken or invalid hyperlinks

What inspectors look for

Auditors assess:

  • consistency across Modules 2, 3, 4 and 5
  • stability in compliance with ICH Q1A/Q1E
  • complete BE studies per EMA/FDA guidance
  • product specifications with technical justification
  • impurity control and toxicological qualification
  • lifecycle management compliance with ICH Q12
  • eCTD free from technical errors

Common deficiencies in Module 3 include unjustified impurity limits, insufficient stability data and overly generic process descriptions.

How to avoid critical deviations

Operational strategies:

  • ensure the QOS is perfectly aligned with S and P sections
  • clearly document CPP, CQA and design space (when applicable)
  • present stability data with trends, graphs and OOS discussion
  • align nonclinical studies with overviews 2.4/2.6
  • ensure CSR are complete, numbered, signed and consistent with the synopsis
  • perform internal review using an eCTD viewer before every submission
  • verify metadata (application number, sequence, description)

Audit Readiness – Essential Documents

Core documents:

  • updated QOS
  • consolidated stability reports
  • analytical and process validation data
  • process description and CTD flowchart
  • CSR and synopses compliant with ICH E3
  • lifecycle-related change controls
  • PLCM template (ICH Q12)
  • checklists for Modules 1–5

Essential records:

  • CTD version tracking
  • eCTD sequence log
  • regulatory decisions, RFI and responses
  • proof of GLP, GMP and GCP compliance

Typical deficiency → Recommended corrective action

Deficiency:
Insufficient stability data or no discussion of stability trends.

Corrective action:
Update section P.8.1 with statistical analysis, shelf-life justification and commitment per P.8.2.
Use graphical trend analyses and reference ICH Q1A/Q1E.

Conclusion

Keep your organisation fully audit-ready. Discover the complete guide on GuideGxP.com.

Back to blog

Looking for something specific?

DISCOVER THE FULL GXP CATALOG